XML 63 R49.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Collaborative Arrangements - Narrative (Details) - USD ($)
$ in Millions
1 Months Ended 12 Months Ended 17 Months Ended 35 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Jan. 31, 2020
Dec. 31, 2019
Mar. 31, 2019
Dec. 31, 2018
Mar. 31, 2018
Dec. 31, 2017
Jul. 31, 2017
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2018
Jan. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Research and development                   $ 9,872 $ 9,752 $ 10,339    
Noncurrent liabilities       $ 11,970   $ 12,041       11,970 12,041   $ 12,041  
Amortization expense for intangible assets                   2,000 3,100 3,200    
Other intangibles, net       14,196   13,104       14,196 13,104   13,104  
Estimated aggregate amortization expense, 2020       1,600           1,600        
Estimated aggregate amortization expense, 2021       1,500           1,500        
Estimated aggregate amortization expense, 2022       1,500           1,500        
Estimated aggregate amortization expense, 2023       1,500           1,500        
Estimated aggregate amortization expense, 2024       1,400           1,400        
Licenses                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Other intangibles, net       2,361   1,673       2,361 1,673   1,673  
Lynparza | Licenses                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Other intangibles, net       955           955        
Lenvima | Licenses                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Other intangibles, net       956           956        
Adempas | Other Intangible Assets, Net                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Intangible assets       883           883        
AstraZeneca                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Upfront and milestone payments                 $ 1,600          
Payments to acquire intangible assets       100   400   $ 250 $ 750          
Research and development                       $ 2,350    
AstraZeneca | Sales-Based Milestones                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Contingent payments collaborative arrangement                   3,100        
AstraZeneca | Regulatory Milestones                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Contingent payments collaborative arrangement                   1,700        
AstraZeneca | Lynparza | Sales-Based Milestones                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Probable future contingent payments collaborative arrangement                   300        
Liabilities       300           300        
Milestone payments made to collaborative partner                   200 250   700  
AstraZeneca | Lynparza | Regulatory Milestones                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Milestone payments made to collaborative partner                   30 140      
Eisai                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Upfront and milestone payments             $ 750              
Payments to acquire intangible assets         $ 325                  
Research and development                     1,400      
Eisai | Sales-Based Milestones                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Contingent payments collaborative arrangement                   3,000        
Eisai | Regulatory Milestones                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Contingent payments collaborative arrangement                   135        
Eisai | Lenvima | Sales-Based Milestones                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Probable future contingent payments collaborative arrangement                   682 268      
Liabilities       $ 682           682        
Milestone payments made to collaborative partner                   50        
Eisai | Lenvima | Regulatory Milestones                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Milestone payments made to collaborative partner                     250      
Eisai | Forecast                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Payments to acquire intangible assets $ 125 $ 200                       $ 650
Bayer AG | Sales-Based Milestones                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Contingent payments collaborative arrangement                   $ 400        
Bayer AG | Adempas | Sales-Based Milestones                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Probable future contingent payments collaborative arrangement                     375      
Noncurrent liabilities           $ 375         375   $ 375  
Milestone payments made to collaborative partner                     $ 350      
Subsequent Event | AstraZeneca | Lynparza | Sales-Based Milestones                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Milestone payments made to collaborative partner     $ 250                      
Subsequent Event | Eisai | Lenvima | Sales-Based Milestones                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Milestone payments made to collaborative partner     $ 150